Vorinostat Recruiting Phase 1 Trials for Acute Myelogenous Leukaemia (AML) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03263936Epigenetic Reprogramming in Relapse/Refractory AML